Molecular profiles of inflammatory myopathies

Neurology

Volumn 59, Issue 8, 2002, Pages 1170-1182

  Greenberg, S A ^a,b   Sanoudou, D ^b   Haslett, J N ^b   Kohane, I S ^b   Kunkel, L M ^b   Beggs, A H ^b   Amato, A A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CELL ADHESION MOLECULE; CYTOKINE; GRANZYME A; GRANZYME B; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSKELETON; DERMATOMYOSITIS; DISEASE CLASSIFICATION; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INCLUSION BODY MYOSITIS; INFLAMMATORY DISEASE; MALE; MUSCULAR DYSTROPHY; MYOPATHY; NEMALINE MYOPATHY; NUCLEOTIDE SEQUENCE; POLYMYOSITIS; PRIORITY JOURNAL; UNINDEXED SEQUENCE;

EID: 0037159180     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.59.8.1170     Document Type: Article

References (65)

1. Amato AA, Barohn RJ. Idiopathic inflammatory myopathies. Neurol Clin 1997;15:615-648.
2. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-713.
3. Pruitt JN II, Showalter CJ, Engel AG. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol 1996;39:139-143.
4. Barohn RJ. The therapeutic dilemma of inclusion body myositis. Neurology 1997;48:567-568.
5. Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to therapy. Neurology 1995;45:1302-1304.
6. Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1996;40:581-586.
7. Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis: observations in 40 patients. Brain 1989;112:727-747.
8. Dalakas MC. Progress in inflammatory myopathies: good but not good enough. J Neurol Neurosurg Psychiatry 2001;70:569-573.
9. Blume G, Pestronk A, Frank B, Johns DR. Polymyositis with cytochrome oxidase negative muscle fibres: early quadriceps weakness and poor response to immunosuppressive therapy. Brain 1997;120:39-45.
10. Levine TD, Pestronk A. Inflammatory myopathy with cytochrome oxidase negative muscle fibers: methotrexate treatment. Muscle Nerve 1998;21:1724-1728.
11. Pegoraro E, Mancias P, Swerdlow SH, et al. Congenital muscular dystrophy with primary laminin alpha2 (merosin) deficiency presenting as inflammatory myopathy. Ann Neurol 1996;40:782-791.
12. Munsat TL, Piper D, Cancilla P, Mednick J. Inflammatory myopathy with facioscapulohumeral distribution. Neurology 1972;22:335-347.
13. McNally EM, Ly CT, Rosenmann H, et al. Splicing mutation in dysferlin produces limb-girdle muscular dystrophy with inflammation. Am J Med Genet 2000;91:305-312.
14. Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993;94:379-387.
15. Carpenter S, Karpati G. Pathology of skeletal muscle, 2nd ed. New York: Oxford University Press, 2001.
16. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990;27:343-56.
17. Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986;314:329-334.
18. Kissel JT, Halterman RK, Rammohan KW, Mendell JR. The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol 1991;48:26-30.
19. Greenberg SA. DNA microarray technology and its application to neurological disorders. Neurology 2001;57:755-761.
20. Alizadeh A, Eisen M, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
21. Alon U, Barkai N, Notterman DA, et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci U S A 1999;96:6745-6750.
22. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-537.
23. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406:536-540.
24. Watson MA, Perry A, Budhjara V, et al. Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res 2001;61:1825-1829.
25. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001;344:539-548.
26. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000;405:857-865.
27. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-491.
28. Debouck C, Goodfellow PN. DNA microarrays in drug discovery and development. Nat Genet 1999;21:48-50.
29. Marton M, DeRisi J, Bennett H, et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat Med 1998;4:1293-1301.
30. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet 1999;21(1 suppl):33-37.
31. Affymetrix GeneChip Analysis Suite User Guide, Version 3.3, 1999.
32. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-14868.
33. The Human Gene Nomenclature Committee. Available at http://www.gene.ucl.ac.uk/nomenclature.
34. CHIP bioinformatics tools. Available at http://bio.chip.org:8080/bio/unchip.
35. Basic Local Alignment Search Tool. Available at http://ncbi.nlm.nih.gov/.
36. Tezak Z, Hoffman EP, Lutz JL, et al. Gene expression profiling in DQA1*0501(+) children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002;168:4154-4163.
37. Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry 2000:68:472-478.
38. Bartoccioni E, Gallucci S, Scuderi F, et al. MHC class I, MHC class II, and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies. Clin Exp Immunol 1994;95:166-172.
39. Wiendl H, Behrens L, Maier S, et al. Muscle fibers in inflammatory myopathies and cultured myoblasts express the non-classical major histocompatibility antigen HLA-G. Ann Neurol 2000;48:679-684.
40. Englund P, Lindroos E, Nennesmo I, et al. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am J Pathol 2001;159:1263-1273.
41. Dalakas MC. Immunopathogenesis of inflammatory myopathies. Ann Neurol 1995;37(suppl 1):S74-S86.
42. Tews DS, Goebel HH. Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 1996;55:342-347.
43. De Bleecker JL, Engel AG. Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol 1994;53:369-376.
44. Choi Y, Dalakas MC. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 2000;54:65-71.
45. Dalakas MC. Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol 1998;55:1509-1512.
46. Lundberg I, Brengman JM, Engel AG. Analysis of cytokine expression in muscle in inflammatory myopathies, dystrophy, and non-weak controls. J Neuroimmunol 1995;63:9-16.
47. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol 1986;19:112-125.
48. Sarkozi E, Askanas V, Johnson SA, Engel WK, Alvarez RB. Beta-amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. Neuroreport 1993;4:815-818.
49. Askanas V, Engel WK, Bilak M, Alvarez RB, Selkoe DJ. Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. Am J Pathol 1994;144:177-187.
50. Askanas V, Serdaroglu P, Engel WK, Alvarez RB. Immunocytochemical localization of ubiquitin in inclusion body myositis allows its light-microscopic distinction from polymyositis. Neurology 1992;42:460-461.
51. Sarkozi E, Askanas V, Engel WK. Abnormal accumulation of prion protein mRNA in muscle fibers of patients with sporadic inclusion-body myositis and hereditary inclusion-body myopathy. Am J Pathol 1994;145:1280-1284.
52. Bilak M, Askanas V, Engel WK. Strong immunoreactivity of alpha 1-antichymotrypsin co-localizes with beta-amyloid protein and ubiquitin in vacuolated muscle fibers of inclusion-body myositis. Acta Neuropathol (Berl) 1993;85:378-382.
53. Mirabella M, Alvarez RB, Engel WK, Weisgraber KH, Askanas V. Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies. Ann Neurol 1996;40:864-872.
54. Askanas V, Sarkozi E, Alvarez RB, McFerrin J, Siddique T, Engel WK. SOD1 gene and protein in vacuolated muscle fibers of s-IBM, h-IBM, and in cultured human muscle after bAPP gene transfer. Neurology 1996;46:487.
55. Tsuruta Y, Furuta A, Taniguchi N, Yamada T, Kira J, Iwaki T. Increased expression of manganese superoxide dismutase is associated with that of nitrotyrosine in myopathies with rimmed vacuoles. Acta Neuropathol (Berl) 2002;103:59-65.
56. Prayson RA, Yu AC. Bcl-2, Bcl-x, and Bax expression by immunohistochemistry in inclusion body myositis: a study of 27 cases. Arch Pathol Lab Med 2001;125:1326-1330.
57. Jaworska-Wilczynska M, Wilczynski GM, Engel WK, Strickland DK, Weisgraber KH, Askanas V. Three lipoprotein receptors and cholesterol in inclusion-body myositis muscle. Neurology 2002;58:438-445.
58. Semino-Mora C, Dalakas MC. Rimmed vacuoles with beta-amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (postpoliomyelitis muscular atrophy): similarities with inclusion body myositis. Hum Pathol 1998;29:1128-1133.
59. Askanas V, Sarkozi E, Bilak M, Alvarez RB, Engel WK. Human muscle macrophages express beta-amyloid precursor and prion proteins and their mRNAs. Neuroreport. 1995;6:1045-1049.
60. Amato AA, Shebert RT. Inclusion body myositis in twins. Neurology. 1998;51:598-600.
61. Sivakumar K, Semino-Mora C, Dalakas MC. An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis: studies in three families. Brain. 1997;120:653-661.
62. Sivakumar K, Dalakas MC. The spectrum of familial inclusion body myopathies in 13 families and a description of a quadriceps-sparing phenotype in non-Iranian Jews. Neurology. 1996;47:977-984.
63. The National Center for Biotechnology Information, Gen-Bank. Available at http://www.ncbi.nlm.nih.gov/UniGene/.
64. Affymetrix Inc. Available at http://www.affymetrix.com/products/gc_U133.html. Accessed on 1/05/02.
65. Hughes TR, Mao M, Jones AR, et al. Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol 2001;19:342-347.